Dhanashree S. Kelkar

Dhanashree S. Kelkar

Auto-generated profile, based on publicly available information

Dhanashree S. Kelkar

McKusick-Nathans Institute of Genetic Medicine, Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
WDW. Brian Dalton
W. Brian Dalton
EHEric Helmenstine
Eric Helmenstine
NWNoel Walsh
Noel Walsh
LGLukasz P. Gondek
Lukasz P. Gondek
DKDhanashree S. Kelkar
Dhanashree S. Kelkar
BPBen Ho Park
Ben Ho Park
Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.